Search Results - "PONNIAH, Sathibalan"

Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence by Brown, Tommy A., Mittendorf, Elizabeth A., Hale, Diane F., Myers, John W., Peace, Kaitlin M., Jackson, Doreen O., Greene, Julia M., Vreeland, Timothy J., Clifton, G. Travis, Ardavanis, Alexandros, Litton, Jennifer K., Shumway, Nathan M., Symanowski, J., Murray, James L., Ponniah, Sathibalan, Anastasopoulou, E. A., Pistamaltzian, N. F., Baxevanis, Constantin N., Perez, Sonia A., Papamichail, Michael, Peoples, George E.

“…Purpose AE37 and GP2 are HER2 derived peptide vaccines. AE37 primarily elicits a CD4+ response while GP2 elicits a CD8+ response against the HER2 antigen…”
Get full text

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence by Mittendorf, Elizabeth A, Ardavanis, Alexandros, Litton, Jennifer K, Shumway, Nathan M, Hale, Diane F, Murray, James L, Perez, Sonia A, Ponniah, Sathibalan, Baxevanis, Constantin N, Papamichail, Michael, Peoples, George E

“…GP2 is a HER2-derived, HLA-A2+ restricted peptide. Phase I studies showed GP2 administered with GM-CSF to be safe and immunogenic. Here we report the primary…”
Get full text

CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients by Lim, Kue Peng, Chun, Nicole Ai Leng, Ismail, Siti Mazlipah, Abraham, Mannil Thomas, Yusoff, Mohd Nury, Zain, Rosnah Binti, Ngeow, Wei Cheong, Ponniah, Sathibalan, Cheong, Sok Ching

“…Regulatory T cells (Tregs), a subset of CD4+ T cells plays a pivotal role in regulating the immune system. An increase in Treg numbers enables cancer…”
Get full text

Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 by Peoples, George E, Holmes, Jarrod P, Hueman, Matthew T, Mittendorf, Elizabeth A, Amin, Asna, Khoo, Steven, Dehqanzada, Zia A, Gurney, Jennifer M, Woll, Michael M, Ryan, Gayle B, Storrer, Catherine E, Craig, Dianna, Ioannides, Constantin G, Ponniah, Sathibalan

“…Purpose: E75 is an immunogenic peptide from the HER2/ neu protein, which is overexpressed in many breast cancer patients. We have conducted two overlapping E75…”
Get full text

The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 by BENAVIDES, Linda C, GATES, Jeremy D, PEOPLES, George E, CARMICHAEL, Mark G, PATEL, Ritesh, HOLMES, Jarrod P, HUEMAN, Matthew T, MITTENDORF, Elizabeth A, CRAIG, Dianna, STOJADINOVIC, Alexander, PONNIAH, Sathibalan

“…Purpose: HER2/ neu , a source of immunogenic peptides, is expressed in >75% of breast cancer patients. We have conducted clinical trials with the HER2/ neu E75…”
Get full text

Results of the first phase 1 clinical trial of the HER‐2/neu peptide (GP2) vaccine in disease‐free breast cancer patients by Carmichael, Mark G., Benavides, Linda C., Holmes, Jarrod P., Gates, Jeremy D., Mittendorf, Elizabeth A., Ponniah, Sathibalan, Peoples, George E.

“…BACKGROUND: HER‐2/neu, overexpressed in breast cancer, is a source of immunogenic peptides that include GP2 and E75. Phase 2 testing of E75 as an adjuvant…”
Get full text

Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma by Chai, San Jiun, Yap, Yoke Yeow, Foo, Yoke Ching, Yap, Lee Fah, Ponniah, Sathibalan, Teo, Soo Hwang, Cheong, Sok Ching, Patel, Vyomesh, Lim, Kue Peng

“…Nasopharyngeal carcinoma (NPC) is highly prevalent in South East Asia and China. The poor outcome is due to late presentation, recurrence, distant metastasis…”
Get full text

Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients by PEOPLES, George E, GURNEY, Jennifer M, HUEMAN, Matthew T, WOLL, Mike M, RYAN, Gayle B, STORRER, Catherine E, FISHER, Christine, SHRIVER, Craig D, IOANNIDES, Constantin G, PONNIAH, Sathibalan

“…E75 is an immunogenic peptide from the HER2/neu protein that is highly expressed in breast cancer. We are conducting a clinical trial of an E75 +…”
Get full text

Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine by HOLMES, Jarrod P, BENAVIDES, Linda C, PONNIAH, Sathibalan, PEOPLES, George E, GATES, Jeremy D, CARMICHAEL, Mark G, HUEMAN, Matthew T, MITTENDORF, Elizabeth A, MURRAY, James L, AMIN, Asna, CRAIG, Dianna, VON HOFE, Eric

“…HER-2/neu is overexpressed in breast cancer and is the source of immunogenic peptides. CD4(+) T-helper peptides for HER-2/neu are being evaluated in vaccine…”
Get full text

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine by Holmes, Jarrod P., Clifton, Guy T., Patil, Ritesh, Benavides, Linda C., Gates, Jeremy D., Stojadinovic, Alexander, Mittendorf, Elizabeth A., Ponniah, Sathibalan, Peoples, George E.

“…BACKGROUND: The authors are conducting clinical trials of the HER‐2/neu E75‐peptide vaccine in clinically disease‐free breast cancer (BC) patients. Their phase…”
Get full text

The GP2 peptide: A HER2/neu-based breast cancer vaccine by Clive, Kevin S., Tyler, Josh A., Clifton, G. Travis, Holmes, Jarrod P., Ponniah, Sathibalan, Peoples, George E., Mittendorf, Elizabeth A.

“…Preclinical studies suggest that GP2, a HER2/neu‐derived peptide, is immunogenic. Subsequent phase I clinical trials demonstrated that GP2‐based vaccines are…”
Get full text

In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients by Chai, San Jiun, Fong, Sammuel Chee Yong, Gan, Chai Phei, Pua, Kin Choo, Lim, Paul Vey Hong, Lau, Shin Hin, Zain, Rosnah Binti, Abraham, Thomas, Ismail, Siti Mazlipah, Abdul Rahman, Zainal Ariff, Ponniah, Sathibalan, Patel, Vyomesh, Cheong, Sok Ching, Lim, Kue Peng

“…Peptide vaccines derived from tumour-associated antigens have been used as an immunotherapeutic approach to induce specific cytotoxic immune response against…”
Get full text

Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer by Mittendorf, Elizabeth A, Storrer, Catherine E, Shriver, Craig D, Ponniah, Sathibalan, Peoples, George E

“…Trastuzumab, an anti-HER2/neu monoclonal antibody, is thought to promote HER2/neu receptor internalization and/or turnover. This study was designed to…”
Get full text

Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/ neu -Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial by Patil, Ritesh, MD, Clifton, Guy T., MD, Holmes, Jarrod P., MD, Amin, Asna, MD, Carmichael, Mark G., MD, Gates, Jeremy D., MD, Benavides, Linda H., MD, Hueman, Matthew T., MD, Ponniah, Sathibalan, PhD, Peoples, George E., MD, FACS

“…Background We have treated disease-free breast cancer patients with an HER2/ neu -derived peptide, E75, as an adjuvant vaccine. E75 was originally described as…”
Get full text

Clinical benefit and safety of boosting the HER2 peptide vaccine (AE37+GM-CSF) in the adjuvant setting to prevent breast cancer recurrence by Schneble, Erika, MD, Berry, John S., MD, Trappey, Alfred F., MD, Vreeland, Timothy J., MD, Clifton, Guy T., MD, Ponniah, Sathibalan, PhD, Papamichail, Michael, MD, PhD, Perez, Sonia, PhD, Peoples, George E., MD, Mittendorf, Elizabeth A., MD, PhD, FACS

Get full text

Biomarker correlation to clinical response in a phase II trial of the HER2 peptide vaccine (AE37+GM-CSF) by Schneble, Erika, MD, Berry, John S., MD, Vreeland, Timothy J., MD, Trappey, Alfred F., MD, Clifton, Guy T., MD, Ponniah, Sathibalan, PhD, Perez, Sonia, PhD, Papamichail, Michael, MD, PhD, Peoples, George E., MD, Mittendorf, Elizabeth A., MD, PhD, FACS

Get full text

Identification of immunogenic MAGED4B peptides for vaccine development in oral cancer immunotherapy by Lim, Kue Peng, Chun, Nicole Ai Leng, Gan, Chai Phei, Teo, Soo-Hwang, Rahman, Zainal Ariff Abdul, Abraham, Mannil Thomas, Zain, Rosnah Binti, Ponniah, Sathibalan, Cheong, Sok Ching

“…The ever-increasing number of tumor-associated antigens has provided a major stimulus for the development of therapeutic peptides vaccines. Tumor-associated…”
Get full text

Identification of a regulatory T cell subset that correlates with in vivo and in vitro immune responses in breast cancer patients receiving a CD4-eliciting, HER2 peptide vaccine (AE37) by Trappey, Alfred Francois, MD, Berry, John S., MD, Mursal, Mohamed, BS, Jama, Yusuf, MS, Zacharia, Athina, MS, Pham, Rebecca, BS, Margulies, Eric, BA, Ponniah, Sathibalan, PhD, Mittendorf, Elizabeth A., MD, FACS, Peoples, George E., MD, FACS

Get full text

Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patients by Mittendorf, Elizabeth A., Clifton, Guy T., Holmes, Jarrod P., Clive, Kevin S., Patil, Ritesh, Benavides, Linda C., Gates, Jeremy D., Sears, Alan K., Stojadinovic, Alexander, Ponniah, Sathibalan, Peoples, George E.

“…BACKGROUND: The authors conducted exploratory phase 1‐2 clinical trials vaccinating breast cancer patients with E75, a human leukocyte antigen (HLA)…”
Get full text

Ets family protein, erg expression in developing and adult mouse tissues by a highly specific monoclonal antibody by Mohamed, Ahmed A, Tan, Shyh-Han, Mikhalkevich, Natallia, Ponniah, Sathibalan, Vasioukhin, Valeri, Bieberich, Charles J, Sesterhenn, Isabell A, Dobi, Albert, Srivastava, Shiv, Sreenath, Taduru L

“…Oncogenic activation of the ETS Related Gene (ERG) in humans was originally identified in subsets of Ewing sarcomas, myeloid leukemias and, recently, in the…”
Get full text